Moderna, päivitys
Moderna on sopinut Samsung Biologics'in kanssa yhteistyösopimuksen. Tämä ja muut positiiviset ilmoitukset aiheuttivat vilkasta keskustelua FinanceYahoo:ssa.
https://finance.yahoo.com/quote/MRNA/community?p=MRNA
Nimim. Bikedude ennakoi yhtiön osakkeen pääsyä S&P 500-indeksiin pian. Sillä voi olla (on todennäköisesti) merkittävä vaikutus kurssiin, kun passiivisina pysyneet suurinvestoijat lähtevät ostoksille.
"In the not to distant future, MRNA should be included in the S&P
500. For those of us dedicated longs, this will provide a nice bump
when all the passive funds & ETF's establish their positions in
accordance with their mandates. Criteria is as follows:
"To be eligible for S&P 500 index inclusion, a company should be a U.S. company,
have a market capitalization of at least USD 11.8 billion,
be highly liquid, have a public float of at least 10% of
its shares outstanding, and its most recent quarter’s
earnings and the sum of its trailing four consecutive
quarters’ earnings must be positive"."
Nimim. Randall ennakoi nopeaa tuloskasvua yhtiölle, jopa yli 300 $:n ennustetta kurssille jo vuonna 2021..
"MRNA will make 10 × 1Q 2021 for 2021. The money is already in the bank prepaid orders. At $2.83 EPS that is $28.30 EPS for 2021. EPS for 2022 will be 3 × 2021. This stock will be over $300.00 per share by the end of 2021. That does not take into account vaccines from Moderna's pipeline hitting the market this year or next."
https://finance.yahoo.com/news/moderna-samsung-biologics-announce-agreement-160000248.html
Sopimus tuotekehityksestä ja massatuotannosta
"CAMBRIDGE, Mass. and INCHEON, South Korea, May 22, 2021 /PRNewswire/ -- Moderna (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Samsung Biologics (KRX: 207940.KS), a leading global CDMO providing a fully integrated end-to-end contract development and manufacturing service, today announced a Manufacturing Services and Supply Agreement in which Samsung Biologics will provide large scale, commercial fill-finish manufacturing for mRNA-1273, Moderna's COVID-19 vaccine."
Wikipedia:/ "A contract manufacturing organization (CMO), sometimes called a contract development and manufacturing organization (CDMO), is a company that serves other companies in the pharmaceutical industry on a contract basis to provide comprehensive services from drug development through drug manufacturing."
Samsung Biologics:in osake ponnahti jo ennakoon, kun mahdollisuus yhteistyökuviosta tuli julkisuuteen, 5-7 päivässä 26%:
Yhtiöllä on vajaa 3'000 työntekijää (Modernalla 90, se on erityisen voimakkaasti verkottumassa).
Viikonlopun uutinen voi/ uutiset voivat nostaa Modernan kurssia voimakkaasti 24.05.2021.
